NCT05228470 2026-01-06
A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.
Pfizer
Phase 2 Completed
Pfizer
National Institutes of Health Clinical Center (CC)
Merck Sharp & Dohme LLC
Brigham and Women's Hospital